| Secukinumab in plaque psoriasis—results of two phase 3 trials RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ... New England Journal of Medicine 371 (4), 326-338, 2014 | 2349 | 2014 |
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo … CL Leonardi, AB Kimball, KA Papp, N Yeilding, C Guzzo, Y Wang, S Li, ... The Lancet 371 (9625), 1665-1674, 2008 | 2028 | 2008 |
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo … KA Papp, RG Langley, M Lebwohl, GG Krueger, P Szapary, N Yeilding, ... The Lancet 371 (9625), 1675-1684, 2008 | 1759 | 2008 |
| Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial K Reich, FO Nestle, K Papp, JP Ortonne, R Evans, C Guzzo, S Li, ... The Lancet 366 (9494), 1367-1374, 2005 | 1360 | 2005 |
| Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial S Tyring, A Gottlieb, K Papp, K Gordon, C Leonardi, A Wang, D Lalla, ... The Lancet 367 (9504), 29-35, 2006 | 1335 | 2006 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1299 | 2017 |
| Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis KA Papp, C Leonardi, A Menter, JP Ortonne, JG Krueger, G Kricorian, ... New England Journal of Medicine 366 (13), 1181-1189, 2012 | 1154 | 2012 |
| Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial A Menter, SK Tyring, K Gordon, AB Kimball, CL Leonardi, RG Langley, ... Journal of the American Academy of Dermatology 58 (1), 106-115, 2008 | 1112 | 2008 |
| Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis New England Journal of Medicine 362, 118-128, 2010 | 1064 | 2010 |
| Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis KB Gordon, A Blauvelt, KA Papp, RG Langley, T Luger, M Ohtsuki, ... New England Journal of Medicine 375 (4), 345-356, 2016 | 991 | 2016 |
| Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe … A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ... Journal of the american academy of dermatology 76 (3), 405-417, 2017 | 946 | 2017 |
| Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials CEM Griffiths, K Reich, M Lebwohl, P Van De Kerkhof, C Paul, A Menter, ... The Lancet 386 (9993), 541-551, 2015 | 921 | 2015 |
| Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) JH Saurat, G Stingl, L Dubertret, K Papp, RG Langley, JP Ortonne, ... British Journal of Dermatology 158 (3), 558-566, 2008 | 912 | 2008 |
| Phase 3 studies comparing brodalumab with ustekinumab in psoriasis M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ... New England Journal of Medicine 373 (14), 1318-1328, 2015 | 898 | 2015 |
| A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction KA Papp, S Tyring, M Lahfa, J Prinz, CEM Griffiths, AM Nakanishi, R Zitnik, ... British Journal of Dermatology 152 (6), 1304-1312, 2005 | 878 | 2005 |
| Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four–week efficacy and safety … A Kavanaugh, I McInnes, P Mease, GG Krueger, D Gladman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009 | 825 | 2009 |
| Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological … C Ritchlin, P Rahman, A Kavanaugh, IB McInnes, L Puig, S Li, Y Wang, ... Annals of the rheumatic diseases 73 (6), 990-999, 2014 | 760 | 2014 |
| Two phase 3 trials of adalimumab for hidradenitis suppurativa AB Kimball, MM Okun, DA Williams, AB Gottlieb, KA Papp, CC Zouboulis, ... New England Journal of Medicine 375 (5), 422-434, 2016 | 757 | 2016 |
| Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy … K Papp, K Reich, CL Leonardi, L Kircik, S Chimenti, RGB Langley, CC Hu, ... Journal of the American Academy of Dermatology 73 (1), 37-49, 2015 | 717 | 2015 |
| A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis A Menter, SR Feldman, GD Weinstein, K Papp, R Evans, C Guzzo, S Li, ... Journal of the American Academy of Dermatology 56 (1), 31. e1-31. e15, 2007 | 683 | 2007 |
Andrew BlauveltInvestigator, Oregon Medical Research CenterVerified email at oregonmedicalresearch.com
